LivaNova PLC (NASDAQ:LIVN) Files An 8-K Regulation FD DisclosureItem 7.01
On September14, 2017, LivaNova PLC (“LivaNova” or the “Company”) issued a press release announcing that the Company is exploring strategic options for its Cardiac Rhythm Management (CRM) Business Franchise as part of the Company’s ongoing efforts to strengthen LivaNova’s position as a leading, innovative medical device company dedicated to extending and improving the lives of patients around the world. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information disclosed under this Item 7.01 shall not be deemed “filed” for any purpose, including for the purposes of Section18 of the United States Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in this Item 7.01 shall not be deemed incorporated by reference into any filing under the Exchange Act or the United States Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.
| Item 7.01 | Financial Statements and Exhibits |
(d) Exhibits
| 99.1 | Press Release, dated September14, 2017. |
LivaNova PLC ExhibitEX-99.1 2 d420446dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 NEWS RELEASE LivaNova to Explore Strategic Options for Cardiac Rhythm Management Business Franchise London,…To view the full exhibit click here
About LivaNova PLC (NASDAQ:LIVN)
LivaNova PLC is a medical technology company. The Company operates through three segments: Cardiac Surgery, Cardiac Rhythm Management (CRM) and Neuromodulation. The Cardiac Surgery business unit is engaged in the development, production and sale of cardiovascular surgery products, including oxygenators, heart-lung machines, perfusion tubing systems and systems for autotransfusion and autologous blood washing. The CRM business unit develops, manufactures and markets products for the diagnosis, treatment and management of heart rhythm disorders and heart failure. CRM offers products, including leads and delivery systems, and information systems. The Neuromodulation business unit designs, develops and markets neuromodulation-based medical devices for the treatment of epilepsy and depression. Through the Neuromodulation business unit, the Company markets its implantable VNS Therapy systems that deliver vagus nerve stimulation therapy for the treatment of epilepsy and depression.
